Mark J. Mann, MD
There have not been designated novel treatment options for patients with nonmetastatic castration-resistant prostate cancer (CRPC) until very recently, explains Mark J. Mann, MD.
State of the Science Summit™ on Prostate Cancer, Mann, an assistant professor of urology at Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discussed the developing treatment landscape for patients with nonmetastatic CRPC.
OncLive®: Please provide an overview of your lecture on the treatment of nonmetastatic CRPC.
: The definition of nonmetastatic CRPC is a patient with a prostate-specific antigen (PSA) that is 2 over the nadir, or a 25% increase from the nadir while the testosterone is still repressed. The next part of the diagnosis is determining whether it is metastatic. That is done with a CT scan and a bone scan, which are standard, but there are new imaging modalities that are starting to come into play, specifically PET scans.
... to read the full story